Int J Angiol
DOI: 10.1055/s-0040-1721403
Rapid Communication

Will Remdesivir Reshape Cardiovascular Practice in COVID 19 Era?

1  Institute of Cardiac and Aortic Disorders, SRM Institutes for Medical Science (SIMS Hospital), Chennai, Tamil Nadu, India
,
Prasanna Karthik Suthakaran
2  Department of General Medicine, Saveetha Medical College Hospital, Chennai, Tamil Nadu, India
,
George Jose Valooran
3  Department of CVTS, Rajagiri Hospital, Kochi, Kerala, India
,
Mohamad Bashir
4  Department of Vascular and Endovascular Surgery, Royal Blackburn Teaching Hospital, Blackburn, Lancashire, United Kingdom of Great Britain and Northern Ireland
› Author Affiliations

Abstract

Infection with the novel coronavirus, SARS-CoV2, produces the clinical syndrome COVID-19. COVID-19 is a systemic illness inducing hyperinflammation and cytokine storm affecting multiple organs including the myocardium which is reflected in elevated cardiac biomarkers such as troponin, lactate dehydrogenase, and creatinine kinase MB. Furthermore, COVID-19 has been implicated in increased predilection to thromboembolic phenomena. Hence, mortality in patients with associated cardiovascular disease has been higher compared with the cohort with no cardiovascular comorbidity. It is entirely unknown how remdesivir will change the facet of cardiovascular medicine and surgery. In the present constantly changing climate, this review of remdesivir and its association with cardiovascular disease is comprehensive as of June 17, 2020 and it highlights the science behind this drug and its potential implications to cardiovascular practice.



Publication History

Received: 20 June 2020

Accepted: 26 October 2020

Publication Date:
03 December 2020 (online)

© 2020. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA